Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech […]readmore
Tags : Lundbeck
Shots: The RELIEF study evaluating the efficacy & safety of VYEPTI (100mg, 30-minute IV infusion) vs PBO in a ratio (1:1) in 480 patients with migraine, administered within 1-6 hrs […]readmore
Shots: The company discontinues P-II proof POC study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms (NCT03793712). The P-II study evaluated two doses of Lu […]readmore
The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care The Center for Drug Evaluation and Research (CDER) […]readmore
1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, […]readmore
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s […]readmore
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. […]readmore
Shots: The MHLW’s approval follows P-III study (NCT02389816) assessing Trintellix (10mg/20mg) vs PBO in 493 patients with recurrent depression in Japan which demonstrated improvement in overall symptoms of depression in […]readmore
Shots: Lundbeck acquires Alder BioPharmaceuticals in the all-cash transaction making a total deal value $1.95B. Alder to receive $18/share as upfront, non-tradeable CVR of $2/share on EMA’s approval of Eptinezumab […]readmore